{"title":"Case Report: Rare Dupilumab-Associated Pulmonary and Extrapulmonary Tuberculosis.","authors":"Weiyan Xu, Jianfeng Zhong","doi":"10.2147/IDR.S540790","DOIUrl":null,"url":null,"abstract":"<p><p>Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), has revolutionized the management of moderate-to-severe atopic dermatitis (AD) by inhibiting signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13). Our case report is about a 71-year-old man with a history of AD who developed pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) after treatment with dupilumab. The mechanism is unclear, but it may be related to the fact that dupilumab inhibits the expression of pro-inflammatory response-related genes and the innate immunity of macrophages, thereby aggravating TB infection. This is the first report of PTB and EPTB associated with dupilumab treatment, and it may be useful for clinicians to enhance TB vigilance in patients receiving dupilumab therapy, particularly in endemic regions.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"5219-5222"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499361/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S540790","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), has revolutionized the management of moderate-to-severe atopic dermatitis (AD) by inhibiting signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13). Our case report is about a 71-year-old man with a history of AD who developed pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) after treatment with dupilumab. The mechanism is unclear, but it may be related to the fact that dupilumab inhibits the expression of pro-inflammatory response-related genes and the innate immunity of macrophages, thereby aggravating TB infection. This is the first report of PTB and EPTB associated with dupilumab treatment, and it may be useful for clinicians to enhance TB vigilance in patients receiving dupilumab therapy, particularly in endemic regions.
期刊介绍：
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
